ERBB2 and breast cancer: Another significant observation from this study was that HER2-positive breast cancer patients with 1-3 cardiovascular toxicity risk factors displayed a minor yet statistically significant elevation in native T1 value following anticancer therapy, in comparison to those without any risk factors.